Antiviral drugs target specific stages of the viral life cycle to inhibit replication and reduce the burden of viral disease. Unlike antibiotics, antivirals are typically virus-specific, and their development has been particularly successful for herpesviruses, influenza, HIV, and hepatitis C.
What Are Antiviral Drugs?
Antiviral agents act at various points in viral replication including attachment, entry, uncoating, genome replication, protein synthesis, assembly, and release. Most antivirals are virostatic, requiring host immune function to clear the infection, and resistance is a significant clinical concern.
Drug Classes and Mechanisms
Anti-herpes agents target viral DNA polymerase. Acyclovir, after phosphorylation by viral thymidine kinase, competitively inhibits and terminates viral DNA chain elongation. Valacyclovir is a prodrug with improved oral bioavailability. These agents are effective against herpes simplex virus and varicella-zoster virus.
Anti-influenza agents include neuraminidase inhibitors (oseltamivir, zanamivir) that block viral release from infected cells. They reduce symptom duration by approximately one day when started within 48 hours of symptom onset. Baloxavir marboxil inhibits the cap-dependent endonuclease of the viral polymerase.
Anti-HIV drugs are used in combination antiretroviral therapy (ART). Nucleoside reverse transcriptase inhibitors (NRTIs) such as tenofovir and emtricitabine are chain terminators. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) including efavirenz and dolutegravir bind directly to reverse transcriptase. Protease inhibitors (darunavir, atazanavir) prevent viral protein cleavage. Integrase strand transfer inhibitors (dolutegravir, bictegravir) block viral DNA integration into the host genome. Entry inhibitors (maraviroc) and fusion inhibitors (enfuvirtide) block viral entry.
Anti-HCV agents are direct-acting antivirals (DAAs) targeting NS3/4A protease, NS5A protein, and NS5B polymerase. Combinations such as sofosbuvir-velpatasvir achieve cure rates exceeding 95 percent across multiple genotypes with minimal side effects.
Anti-CMV agents include ganciclovir and its prodrug valganciclovir, which inhibit viral DNA polymerase after phosphorylation by viral kinases. Foscarnet and cidofovir are alternatives for resistant infections.
Therapeutic Uses
Herpes simplex infections are treated with episodic or suppressive acyclovir. Influenza benefits from early neuraminidase inhibitor therapy in high-risk patients. HIV requires lifelong combination ART with at least two active agents from different classes. Hepatitis C is now curable with eight to twelve weeks of DAA therapy.
Adverse Effects
Acyclovir is generally well tolerated but may cause nephrotoxicity with rapid intravenous infusion. Oseltamivir causes nausea and vomiting. Antiretroviral drugs have class-specific toxicities: NRTIs cause mitochondrial toxicity and lactic acidosis; NNRTIs cause rash and hepatotoxicity; protease inhibitors cause metabolic syndrome including lipodystrophy and insulin resistance; integrase inhibitors have a favorable metabolic profile.
Key Clinical Considerations
Antiviral resistance emerges with suboptimal therapy, particularly in immunocompromised patients. HIV resistance testing guides ART selection. Adherence to antiretroviral therapy is critical for sustained viral suppression and prevention of resistance. Hepatitis C DAAs have revolutionized treatment but remain expensive, limiting global access.
Conclusion
Antiviral pharmacology has advanced dramatically, transforming HIV from a fatal illness to a manageable chronic condition and curing hepatitis C. Continuing research targets emerging viruses and the challenge of antiviral resistance through novel mechanisms and combination strategies.
